PDS Biotechnology (NASDAQ:PDSB) Raised to Sell at StockNews.com

PDS Biotechnology (NASDAQ:PDSB) was upgraded by equities researchers at StockNews.com to a “sell” rating in a research note issued to investors on Monday.

A number of other brokerages have also recently issued reports on PDSB. HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of PDS Biotechnology in a report on Wednesday, October 11th. B. Riley restated a “buy” rating on shares of PDS Biotechnology in a report on Friday, October 6th. Finally, Oppenheimer decreased their price target on PDS Biotechnology from $23.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday, November 15th.

PDS Biotechnology Trading Up 0.3 %

Shares of NASDAQ:PDSB traded up $0.02 during trading on Monday, reaching $6.31. 409,291 shares of the stock were exchanged, compared to its average volume of 613,017. The company has a debt-to-equity ratio of 0.96, a quick ratio of 8.02 and a current ratio of 6.21. PDS Biotechnology has a 12-month low of $3.80 and a 12-month high of $13.65. The firm has a market cap of $196.29 million, a price-to-earnings ratio of -3.69 and a beta of 1.97. The firm’s 50-day moving average price is $4.89 and its 200 day moving average price is $5.66.

Hedge Funds Weigh In On PDS Biotechnology

Institutional investors have recently made changes to their positions in the business. Rockefeller Capital Management L.P. acquired a new position in shares of PDS Biotechnology in the 4th quarter valued at approximately $45,000. Strs Ohio acquired a new position in shares of PDS Biotechnology in the 2nd quarter valued at approximately $29,000. Allspring Global Investments Holdings LLC acquired a new position in shares of PDS Biotechnology in the 3rd quarter valued at approximately $30,000. Cary Street Partners Investment Advisory LLC raised its position in shares of PDS Biotechnology by 187.7% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 6,131 shares of the company’s stock valued at $31,000 after purchasing an additional 4,000 shares in the last quarter. Finally, BNP Paribas Arbitrage SNC acquired a new position in shares of PDS Biotechnology in the 2nd quarter valued at approximately $37,000. 25.78% of the stock is owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.